Peru had the second-highest number of COVID-19 cases in Latin America. After the first wave, Peru registered more than 900,000 cases of COVID-19 and more than 36,000 confirmed deaths from the disease. Tumbes, a border area with poor sanitation and not enough water, had the fifth highest death rate. The cross-sectional analytic study aimed: a) to assess seroprevalence of COVID-19 after the first wave; b) to assess sociodemographic determinants and symptoms associated with a positive COVID-19 antibody lateral flow test.

During the first wave, COVID-19 had devastating effects on developing countries like Peru, which reported more than 900,000 cases of the disease and more than 36,000 confirmed deaths from it. The informal settlements are counted in COVID-19 regional statistics, but they are very different from the rest of the region in terms of sanitation, access to water and sewage, housing conditions, and others. To make good decisions about public health, it is important to understand how the disease is spread in informal settlements. We did an observational, cross-sectional study in Puerto Pizarro, a remote port village in Tumbes, from November 11, 2020, to November 30, 2020, to assess the seroprevalence of COVID-19 after the first wave, as well as the sociodemographic factors and symptoms linked to a positive COVID-19 antibody lateral flow test. 1391 people older than 2 years old were given census a...

No description

Objective: To describe the frequency of HAIs and the use of antibiotics in a COVID ICU in northern Peru. Material and Methods: cross-sectional descriptive study. 85 stories were reviewed. Results: median age= 57 years, IQR (49-78); 70% men; 74/85 on a ventilator, median in days= 13 (IQR=7-45). HAI frequency: 28.2%: Ventilator-associated pneumonia 79.1%; 26/85 had at least one culture: 22/26 bronchial secretions: 10/26 Acinetobacter baumani, 10/26 Pseudomonas Aeruginosa; 8/10 of Acinetobacter and 5/10 of Pseudomonas were multidrug resistant; 100% of patients received antibiotics; 63% Carbapenems (36% Imipenem and 27% Meropenem) and 22% third-class cephalosporins (14% Ceftazidime and 8% Ceftriaxone); mortality: 30.6%. Of the 19 VAP, 7/19 were due to Acinetobacter Baummani and 10/19 due to Pseudomonas Aeruginosa. Of the deceased, 19% had Acinetobacter baumani and 11% had Pseudomonas Aerugin...

Sr. Editor, En el Perú, estamos viviendo una de las peores epidemias de dengue. Hasta junio del 2023, hubo 126 726 casos, 51% confirmados y 132 fallecidos. Piura, en el norte peruano, concentra la más alta frecuencia de fallecidos con 31,7% (1). A pesar de que la letalidad es menor al 1%, un tamizaje inadecuado de la severidad y un tratamiento conservador pueden incrementarla (2).

Objetivo: a) evaluar la seroprevalencia de SARS-CoV-2 al final de la segunda ola; b) determinar su distribución por grupos de edad y los determinantes de salud asociados a la seropositividad. Materiales y Método: Un estudio realizado en un asentamiento humano de Tumbes entre diciembre de 2021 y enero de 2022 muestreó individuos mayores de 2 años en uno de cada cuatro hogares. Se tomó muestras de sangre por punción-digital y se realizó encuestas sintomáticas. Resultados: La seroprevalencia ajustada tras la segunda ola se duplicó (50.15%, IC 95% [45,92-54,40]), comparado con la primera ola (24.82%, IC 95% [22,49-27,25]). Las mujeres mantuvieron una mayor seroprevalencia (53.89; IC 95% [48,48-59,23] vs. 45.49; IC 95% [38,98-52,12], p = 0,042) comparado con los hombres. Los menores de 18 años presentaron mayor seropositividad IgG: el grupo de 12-17 años durante la segunda ola (85,...

Objective: a) to assess the seroprevalence of SARS-CoV-2 at the end of the second wave; b) to determine the distribution by age group and health determinants associated with seropositivity. Material and Methodology: A study performed in a Tumbes' settlement between December 2021–January 2022 sampled individuals over 2 years old from one to every four households. We collected finger-prick blood samples and conducted symptom surveys. Results: The adjusted seroprevalence after the second wave increased by twofold (50.15%, 95% CI[45.92–54.40]), compared with the first wave (24.82 %, 95%CI [22.49–27.25]). Females maintained a higher seroprevalence (53.89; 95% CI[48.48-59.23]) vs. 45.49; 95% CI [38.98-52.12], p=0.042) compared to males. Those under 18 years of age had the highest IgG seropositivity: the 12–17 age group during the second wave (85.14%) and the 2–11 age group (25.25%) d...